Analyst Sarah James from Cantor Fitzgerald has once again affirmed Health Catalyst (NASDAQ: HCAT) with an “Overweight” rating and a $16 price target on March 5, 2024. This reiteration reflects a strong belief in the company’s future performance. Cantor Fitzgerald first began covering Health Catalyst with an “Overweight” recommendation on August 1, 2023, and has consistently maintained this rating, including on September 14, 2023. The ongoing confidence in Health Catalyst’s growth potential and market value is evident through the consistent rating and price target.
HCAT Stock Shows 7.15% Increase in Price on March 5: Factors Driving Positive Momentum
On March 5, 2024, HCAT stock showed some positive momentum as it closed the trading day with a 7.15% increase in price. Throughout the day, the price of HCAT shares rose by $0.59, bringing it to a closing price higher than its opening price.
Investors should take note of the price momentum and consider the factors driving the increase in price on March 5. It is important to conduct further research and analysis to determine if this positive momentum is sustainable in the long term. Keeping an eye on market trends, company performance, and overall economic conditions can help investors make informed choices when it comes to trading HCAT stock.
HCAT Stock Performance and Financial Results for March 5, 2024: Revenue Up, Net Income Down
HCAT stock had a mixed performance on March 5, 2024, as the company reported its financial results for the past year and the fourth quarter. According to data from CNN Money, HCAT’s total revenue for the past year was $295.94 million, with a significant increase of 7.13% compared to the previous year. However, the total revenue for the fourth quarter was $75.08 million, which remained flat compared to the previous quarter.
On the other hand, HCAT reported a net income of -$118.15 million for the past year, with a notable increase of 14.01% compared to the previous year. The net income for the fourth quarter was -$30.31 million, which showed a 0.0% increase compared to the previous quarter.
In terms of earnings per share (EPS), HCAT reported a figure of -$2.09 for the past year, showing an increase of 20.29% compared to the previous year. However, the EPS for the fourth quarter was -$0.53, which represented a decrease of 35.75% compared to the previous quarter.
Investors and analysts will be closely monitoring HCAT’s future financial performance to assess the company’s growth prospects and stock valuation.
